Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...
From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today ...
An update from Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) is now available. Nanjing Leads Biolabs Co., Ltd. announced that five of its ...
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding ...
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...
Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
Canada's recent restrictions on international student permits have significantly affected applicants from India, according to ...
The Unfiltered Investor brings a refreshing edge, designed to help readers navigate today’s AI-driven volatility with ...
When it comes to promotion and tenure, don’t just describe your research—explain and quantify its impact.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback